Global Marijuana Market Could Reach $18.6 Billion by 2027: UN Report

Dec.12.2022
Global Marijuana Market Could Reach $18.6 Billion by 2027: UN Report
UNCTAD predicts the global cannabis market could reach $18.6 billion by 2027, if key issues are addressed.

According to a comprehensive industry report by the United Nations Conference on Trade and Development (UNCTAD), the global cannabis market could reach $18.6 billion by 2027 if countries around the world take action to clarify the legal status of marijuana and address other key issues.


According to a report from Hemp Today, citing data from Krungsri Research Intelligence, a research unit under the Bank of Ayudhya based in Bangkok, the market value of cannabis in the next five years could double the estimated $4.7 billion in 2020.


The report of the trade development conference covers:


Information: The authors of the report suggest that the cannabis industry needs increased transparency, including public data on all cannabis production outputs, specific country/region data, and pricing information. "At an international level, it is clear that the availability and accessibility of information needs to be improved. Efforts should be made to improve the current state of information on all aspects of this commodity.


The report suggests that other categories should be included, such as hemp seeds, hemp seed oil, hemp seed products, cannabis resin, and essential oils.


Sustainability: The report also indicates that environmental and social factors are "key to the success of any cannabis-related policy" and should therefore be considered within a broader legal and regulatory framework.


The report states that "to ensure the sustainable development of the global cannabis industry, cannabis cultivation can provide environmental benefits that can be taken into account in policies aimed at mitigating the impacts of climate change and restoring healthy ecosystems.


The report indicates that cannabis cultivation could potentially maximize land use and also increase income for farmers and rural communities, particularly in developing countries.


Industry Strategy: The Trade and Development Conference suggests that most regions of the world should consider a comprehensive cannabis cultivation strategy, stating that "given the relatively small size of the cannabis market and its inherent economic constraints, this approach is more viable." The document also notes that the comprehensive cultivation approach may lead to business opportunities in both primary and secondary markets, and that cannabis cultivation can further be monetized through the integration of voluntary carbon credit programs.


This 84-page report outlines the steps that the government can take to utilize the economic and social potential of marijuana, categorizes industrial hemp by output type, and demonstrates how the derivative products of this cannabis sub-industry are reflected in trade statistics.


According to the report, the cannabis value chain can promote growth in rural areas and contribute to manufacturing and food processing industries. However, in order to fully exploit this potential, countries may have to take specific actions. This represents the first international governmental organization document promoting the use of industrial hemp.


The report also addresses the legal issues surrounding marijuana. It notes that clarifying the legal status of marijuana as a non-narcotic substance is the first step the government should take in order to minimize legal and financial risks for producers.


The report suggests that all countries should permit the cultivation of non-intoxicating C. Sativa L. strains, despite the possibility of strict government control. Additionally, a method that promotes overall production and usage, rather than field THC thresholds, should be adopted for the benefit of the final product.


Alternatively, legislators could increase the THC threshold for "field" crops to the scientifically recognized non-toxic level. The report states, "This would increase the variety of strains available for use in the cannabis production chain, thus actually increasing the likelihood of cultivating strains that are best suited to specific environmental conditions and characteristics.


The report also suggests that additional production restrictions imposed by the regulatory framework must be identified and a regional cooperation strategy should be developed to establish a viable and sustainable value chain.


2FIRSTS will continue to follow and report on this topic, with future updates available on the "2FIRSTSAPP." Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
Germany Probes 7.6 Million Illegal Vape Case With Estimated €33.3 Million Tax Loss; Four Chinese Manufacturer Employees Under Investigation, Some Packaging in Enforcement Images Resembles FUMOT Products
German prosecutors and customs authorities are conducting a criminal investigation into an alleged cross-border organised vape network. Authorities say that between January 2024 and March 2025, four employees of an unnamed Chinese e-cigarette manufacturer allegedly built a network of sales agents and wholesalers that brought more than 7.6 million nicotine disposable vapes into Germany, causing an estimated €33.3 million in excise-tax losses. The manufacturer has not been named. Some products visible in enforcement images have packaging resembling products from FUMOT’s portfolio. European regulatory records from 2024, FUMOT’s public overseas-sales materials and records involving German vape importer and distribution company Zamu-Pro GmbH also show FUMOT/RandM products and German distribution activity during the period covered by the investigation.
Sep.21
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine Raises Excise Stamp Fees for Tobacco, Heated Tobacco and Vape Liquids by 30.5% as Parliament Backs E-Excise Delay to 2027
Ukraine's Cabinet of Ministers adopted Resolution No. 1259 on October 15, 2026, increasing excise stamp production fees for tobacco products and e-cigarette liquids by approximately 30.5%, from UAH 0.1643 to UAH 0.2144 per stamp. Fees for alcoholic beverages rose by about 30.2%. Separately, Ukraine's parliament passed Bill No. 15532 on October 13, proposing to postpone the full implementation of electronic excise stamps and traceability for alcohol, tobacco and e-cigarette liquids from November 1, 2026, to July 1, 2027. Parliament cited additional testing, configuration and integration requirements. The bill was sent to the president for signature on October 19.
Regulations
Oct.21
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11